JP2025011315A5 - - Google Patents

Info

Publication number
JP2025011315A5
JP2025011315A5 JP2024185935A JP2024185935A JP2025011315A5 JP 2025011315 A5 JP2025011315 A5 JP 2025011315A5 JP 2024185935 A JP2024185935 A JP 2024185935A JP 2024185935 A JP2024185935 A JP 2024185935A JP 2025011315 A5 JP2025011315 A5 JP 2025011315A5
Authority
JP
Japan
Prior art keywords
cancer
composition
seq
therapeutic agents
additional therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024185935A
Other languages
English (en)
Japanese (ja)
Other versions
JP7766162B2 (ja
JP2025011315A (ja
Filing date
Publication date
Priority claimed from JP2020550713A external-priority patent/JP7328983B2/ja
Application filed filed Critical
Publication of JP2025011315A publication Critical patent/JP2025011315A/ja
Publication of JP2025011315A5 publication Critical patent/JP2025011315A5/ja
Priority to JP2025181096A priority Critical patent/JP2026016604A/ja
Application granted granted Critical
Publication of JP7766162B2 publication Critical patent/JP7766162B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024185935A 2018-03-22 2024-10-22 抗il-27抗体及びその使用 Active JP7766162B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025181096A JP2026016604A (ja) 2018-03-22 2025-10-27 抗il-27抗体及びその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862646496P 2018-03-22 2018-03-22
US62/646,496 2018-03-22
JP2020550713A JP7328983B2 (ja) 2018-03-22 2019-03-22 抗il-27抗体及びその使用
JP2023078028A JP7742377B2 (ja) 2018-03-22 2023-05-10 抗il-27抗体及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023078028A Division JP7742377B2 (ja) 2018-03-22 2023-05-10 抗il-27抗体及びその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025181096A Division JP2026016604A (ja) 2018-03-22 2025-10-27 抗il-27抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2025011315A JP2025011315A (ja) 2025-01-23
JP2025011315A5 true JP2025011315A5 (https=) 2025-09-03
JP7766162B2 JP7766162B2 (ja) 2025-11-07

Family

ID=67987990

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020550713A Active JP7328983B2 (ja) 2018-03-22 2019-03-22 抗il-27抗体及びその使用
JP2023078028A Active JP7742377B2 (ja) 2018-03-22 2023-05-10 抗il-27抗体及びその使用
JP2024185935A Active JP7766162B2 (ja) 2018-03-22 2024-10-22 抗il-27抗体及びその使用
JP2025181096A Pending JP2026016604A (ja) 2018-03-22 2025-10-27 抗il-27抗体及びその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020550713A Active JP7328983B2 (ja) 2018-03-22 2019-03-22 抗il-27抗体及びその使用
JP2023078028A Active JP7742377B2 (ja) 2018-03-22 2023-05-10 抗il-27抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025181096A Pending JP2026016604A (ja) 2018-03-22 2025-10-27 抗il-27抗体及びその使用

Country Status (13)

Country Link
US (3) US11332524B2 (https=)
EP (1) EP3768317A4 (https=)
JP (4) JP7328983B2 (https=)
KR (2) KR20250160366A (https=)
CN (3) CN112512571B (https=)
AU (1) AU2019239324A1 (https=)
BR (1) BR112020018918A2 (https=)
CA (1) CA3093740A1 (https=)
IL (2) IL326896A (https=)
MA (1) MA52094A (https=)
MX (2) MX2020009879A (https=)
SG (1) SG11202008707YA (https=)
WO (1) WO2019183499A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112512571B (zh) 2018-03-22 2025-02-07 表面肿瘤学有限责任公司 抗il-27抗体及其用途
EP3894440A4 (en) * 2018-12-13 2022-09-07 Surface Oncology, Inc. ANTI-IL-27 ANTIBODIES AND USES THEREOF
MX2022003719A (es) * 2019-09-25 2022-04-26 Surface Oncology Inc Anticuerpos anti-il-27 y sus usos.
US12240897B2 (en) * 2020-09-22 2025-03-04 Institute For Cancer Research Treatment of non-alcoholic steatohepatitis (NASH) with IL-27 antibody
WO2022236134A1 (en) * 2021-05-07 2022-11-10 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
US20240025987A1 (en) * 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies
US20240026001A1 (en) * 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6001329A (en) 1996-05-06 1999-12-14 Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
US7148330B2 (en) 1999-07-30 2006-12-12 Schering Corporation Binding compounds for IL-27
EP1390741B1 (en) * 2001-04-17 2012-10-31 Abmaxis, Inc. Structure-based construction of human antibody library
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US20050214296A1 (en) * 2004-02-17 2005-09-29 Schering Corporation Methods of modulating cytokine activity; related reagents
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB-特异性抗体及其使用方法
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP1987837A1 (en) * 2007-05-02 2008-11-05 Technische Universität Dresden Medizinische Fakultät Carl Gustav Carus Pharmaceutical composition for increasing insulin secretion from pancreatic ß-cells
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Pd−1アンタゴニストおよび感染性疾患を処置するための方法
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011133931A1 (en) * 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
AU2012205384B2 (en) * 2011-01-14 2015-09-10 Five Prime Therapeutics, Inc. IL-27 antagonists for treating inflammatory diseases
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-pd-l1 항체 및 그의 용도
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
WO2014070874A1 (en) 2012-10-31 2014-05-08 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗her2表位之單株抗體及其使用之方法
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
CN112512571B (zh) 2018-03-22 2025-02-07 表面肿瘤学有限责任公司 抗il-27抗体及其用途

Similar Documents

Publication Publication Date Title
JP2025011315A5 (https=)
Koganemaru et al. U3-1402, a novel HER3-targeting antibody–drug conjugate, for the treatment of colorectal cancer
Yang et al. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer
Li et al. IDO1: an important immunotherapy target in cancer treatment
Massari et al. Immune checkpoint inhibitors for metastatic bladder cancer
Xie et al. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy
Antonia et al. Immuno-oncology combinations: a review of clinical experience and future prospects
RU2723021C2 (ru) Применение плинабулина в комбинации с ингибиторами контрольной точки иммунного ответа
KR20220044481A (ko) 암 면역요법을 위한 조성물 및 방법
JP2024178243A (ja) 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ
EP3641770A1 (en) Methods for treating cancer
CA3101340A1 (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof
JP2020514289A5 (https=)
CN107801379A (zh) 抗癌剂
JP2021518138A5 (https=)
JP2023548051A (ja) 肺がんのためのlag-3アンタゴニスト療法
JP2022549854A5 (https=)
Valdivia et al. Treatment strategies in cervical cancer: treatment of advanced disease
Gonsalves et al. Targeted anti-cancer therapy in the elderly
Zheng et al. Navigating through novelties concerning mCRC treatment—the role of immunotherapy, chemotherapy, and targeted therapy in mCRC
Rao et al. Molecular-targeted therapies in head and neck cancer
JP2024516970A5 (https=)
CA3214753A1 (en) Dosing of bispecific t cell engager
Mcgovern et al. 448 Discovery of clinical candidate IK-175, a selective orally active AHR antagonist
Al-Batran et al. Recent advances and future trends in the targeted therapy of metastatic gastric cancer